Sponsor
Hunan Cancer Hospital
Clinical research sponsor
How to interpret these research links
Connected source recordsThe exact organization name Hunan Cancer Hospital appears in 51 distinct published trial records. The links retain registry-reported sponsor and collaborator roles; differently spelled legal entities are not automatically merged. Recruiting status describes the current published registry snapshot, not an independently verified availability guarantee.
Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.
Advertisement
Clinical trials
51 shownPrecision Navigation to Improve Community Cancer Screening ParticipationNCT07676383 · lead sponsor · 2026-08-04
RECRUITINGFirmonertinib Combined With Definitive Radiotherapy in Stage III Unresectable EGFR Uncommon Mutant Pulmonary AdenocarcinomaNCT07314216 · lead sponsor · 2026-06-22
RECRUITINGImmunonutrition Reduces Acute Esophagitis After Thoracic Radiotherapy in Lung CancerNCT06840704 · lead sponsor · 2025-02-25
RECRUITINGAnlotinib-based Combination Therapy in Patients with Hormone Receptor-positive（HR+） Metastatic Breast Cancer(MBC) .NCT06734533 · lead sponsor · 2024-12-05
RECRUITINGUtidelone (UTD1) Plus Capecitabine in Non-pCR TNBC After Neoadjuvant TherapyNCT06385990 · lead sponsor · 2024-03-29
RECRUITINGA Trial of Sugemalimab and Chemotherapy in Unresectable Stage III NSCLCNCT05940532 · lead sponsor · 2023-06-14
RECRUITINGUTD1 Combined With Capecitabine in Metastatic HER2-negative Breast Cancer Patients With Brain MetastasesNCT05535413 · lead sponsor · 2023-01-01
RECRUITINGReal-World Study on CDK4/6 Inhibitors Combined With Endocrine Therapy and Subsequent Treatment in HR+/HER2- MBC.NCT06033287 · lead sponsor · 2023-01-01
RECRUITINGReal-World Study of Post-Resistance Treatment Strategies in Advanced Breast Cancer Following CDK4/6i, PIK3CA Inhibitors, or T-DXdNCT07073755 · lead sponsor · 2023-01-01
RECRUITINGEvaluation of Treatment Efficacy by Circulating Tumor Cell Phenotype Surveillance in Breast Cancer PatientsNCT05326295 · lead sponsor · 2019-03-01
RECRUITINGRucaparib Monoclonal Antibody for Lorlatinib-Induced Hypercholesterolemia / MixedNCT07674368 · lead sponsor · 2026-07-10
NOT_YET_RECRUITINGA Trial to Evaluate Sacituzumab Govitecan in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Metastatic Breast Cancer Progressed on CDK4/6 InhibitorsNCT07163481 · lead sponsor · 2025-10-01
NOT_YET_RECRUITINGLorlatinib in ROS1+ NSCLC With Brain MetastasisNCT07083687 · lead sponsor · 2025-08-15
NOT_YET_RECRUITING18F-FES PET/CT in the Treatment Planning, and Response Assessment of ER-Positive Breast CancerNCT07859046 · lead sponsor · 2024-05-09
ENROLLING_BY_INVITATIONReal-world First-line Serplulimab-based Immunochemotherapy for Extensive-stage Small Cell Lung CancerNCT06748495 · lead sponsor · 2024-02-05
ACTIVE_NOT_RECRUITINGA Real-world Study of Inetetamab for First-line Treatment of MBCNCT05980208 · lead sponsor · 2023-09-01
NOT_YET_RECRUITINGTucidinostat and Nab-paclitaxel in Advanced HR+/HER2- Breast CancerNCT05633914 · lead sponsor · 2023-02-07
UNKNOWNReal-world Study of Pyrotinib in Neoadjuvant Therapy for HER2-positive Breast CancerNCT05561686 · lead sponsor · 2022-10-01
UNKNOWNAnlotinib Plus Penpulimab in Advanced Non-Small-Cell Lung Cancer Previously Treated With PD-1/PD-L1 InhibitorsNCT05460481 · lead sponsor · 2022-06-12
UNKNOWNAnlotinib Plus Penpulimab as Second-line Treatment for Patients With Small Cell Lung Cancer After Failure of Platinum-based ChemotherapyNCT05001971 · lead sponsor · 2021-01-30
COMPLETEDSafety and Efficacy of Eribullin or Eribulin Combined With Anlotinib in Metastatic Breast CancerNCT05206656 · lead sponsor · 2020-10-09
COMPLETEDClinical Study of Camrelizumab Combined With APatinib and Albumin Paclitacxel in Patients With Advanced Lung AdenocarcinomaNCT04459078 · lead sponsor · 2020-08-26
UNKNOWNReal World Study on the Efficacy and Safety of Anti-HER2 TherapyNCT05367739 · lead sponsor · 2020-06-01
COMPLETEDPyrotinib in Combination With Letrozole in Patients With HER2-Positive, ER-Positive Metastatic Breast CancerNCT04407988 · lead sponsor · 2019-11-06
UNKNOWNAssessing Safety and Efficacy of Sintilimab and Metformin Combination Therapy in SCLCNCT03994744 · lead sponsor · 2019-08-20
UNKNOWNClinical Study of PD-1 Monoclonal Antibody SHR-1210 and Apatinib in Advanced NSCLC, Soft Tissue Sarcoma, and Uterine CancerNCT04239443 · lead sponsor · 2019-01-30
UNKNOWNAnlotinib Plus Docetaxel for the Treatment of EGFR Wild-type Advanced Non-small-cell Lung CancerNCT03624309 · lead sponsor · 2018-10-15
UNKNOWNCirculating Tumor DNA (ctDNA)-Guided Late-Line Treatment in Patients With Late-Stage Breast CancerNCT05427617 · lead sponsor · 2016-12-01
COMPLETEDClinical Application of Circulating Tumor DNA (ctDNA) in Patients With Late-stage Breast CancerNCT05079074 · lead sponsor · 2016-12-01
COMPLETEDA Study of BEBT-209 Plus Chemotherapy in Patients With Locally Advanced or Metastatic Triple-Negative Breast CancerNCT07544056 · collaborator · 2026-06-04
RECRUITINGHypofractionated Radiation Fractionation in Breast Cancer Patients With Implant-Based ReconstructionNCT06830083 · collaborator · 2025-01-30
RECRUITINGStudy on Human Bioequivalence of Triprerelin Acetate for InjectionNCT06683066 · collaborator · 2024-12-04
RECRUITINGEfficacy and Resistance Mechanisms of IP in NSCLC With Leptomeningeal MetastasesNCT06440954 · collaborator · 2024-05-01
RECRUITINGPatient-Reported Outcome and Safety Between Preoperative and Postmastectomy Radiotherapy in DIEP Flap ReconstructionNCT05512286 · collaborator · 2022-08-25
RECRUITINGUtidelone Versus Docetaxel in HER2-negative Locally Advanced or Metastatic Breast CancerNCT05430399 · collaborator · 2022-06-21
RECRUITINGExploring the Mechanism of Primary Resistance to Third-generation EGFR-TKIs as First-line Treatment in EGFR-positive Advanced NSCLC (PRECISE Study)NCT05598528 · collaborator · 2021-09-28
RECRUITINGThe Effectiveness and Safety of SBRT in the Treatment of Patients With MPLC After Surgery (SMILE)NCT05113017 · collaborator · 2021-07-01
RECRUITINGSurgery vs. No Surgery for Primary Tumor in De Novo Stage IV Breast Cancer With Solitary Bone MetastasesNCT07687225 · collaborator · 2026-09-01
NOT_YET_RECRUITINGA Prospective, Non-interventional Cohort Study of Subsolid Pulmonary NodulesNCT06458673 · collaborator · 2024-12-01
NOT_YET_RECRUITINGLorlatinib as Neoadjuvant Treatment in Stage IB-IIIB ALK-rearranged Non-Small Cell Lung CancerNCT06682884 · collaborator · 2024-11-15
NOT_YET_RECRUITINGLiposomal Irinotecan Combination Regimen for First-line Treatment of Small Cell Lung CancerNCT06462105 · collaborator · 2024-07-05
NOT_YET_RECRUITINGStudy of Cadonilimab Combined With Bevacizumab and Chemotherapy for Advanced Nonsquamous Non-small Cell Lung Cancer Patients With Untreated Brain MetastasesNCT05812534 · collaborator · 2023-12-01
UNKNOWNSurufatinib Combined With Serplulimab Plus Chemotherapy in the Treatment of Extensive-stage Small Cell Lung CancerNCT05882630 · collaborator · 2023-06-01
UNKNOWNTGRX-326 Chinese Phase II for Advanced Non-small Cell Lung Cancer (NSCLC)NCT05955391 · collaborator · 2023-01-18
ACTIVE_NOT_RECRUITINGPhase II Study of Niraparib in Metastatic TNBC Patients With Homologous Recombination DeficiencyNCT05461690 · collaborator · 2022-09-01
UNKNOWNctDNA Analysis to Monitor the Risk of Progression After First-line Immunotherapy in Patients With Advanced NSCLCNCT05198154 · collaborator · 2022-01-24
ACTIVE_NOT_RECRUITINGBioequivalence Study of Doxorubicin Hydrochloride Liposome Injection (Lipodox®) in Chinese PatientsNCT05273944 · collaborator · 2021-07-28
UNKNOWNA Study of Concurrent Chemoradiation With Atezolizumab in Participants With Untreated Extensive-Stage (ES) Small Cell Lung Cancer (SCLC)NCT04636762 · collaborator · 2020-06-01
COMPLETEDPhase I Study of BEBT-209 in Women With Advanced Breast CancerNCT06047184 · collaborator · 2019-07-15
COMPLETEDEfficacy of Tamoxifen Versus Toremifene in CYP2D6 IM/PM of Premenopausal Patients With ER-positive Early Breast CancerNCT03351062 · collaborator · 2017-11-01
UNKNOWNSafety, Tolerability, and Pharmacokinetics of Proxalutamide Therapy in Women With Metastatic Breast CancerNCT04103853 · collaborator · 2017-09-06
COMPLETEDDrugs studied in this sponsor's trials
8 mapped RxNorm conceptsThese drug records are connected through ClinicalTrials.gov studies listing Hunan Cancer Hospital as a sponsor, collaborator or responsible party. Each count is the number of distinct trials containing the mapped drug intervention. This does not establish that the organization manufactures, owns, sells or developed the drug.
docetaxel2
lorlatinib 100 MG2
eribulin mesylate1
fulvestrant1
metformin1
niraparib1
tamoxifen1
toremifene1
docetaxel RxCUI 72962 · Lead sponsor in 1 linked trial(s) · 1 currently recruiting
2 trials
lorlatinib 100 MG RxCUI 2103176 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting
2 trials
eribulin mesylate RxCUI 1045452 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting
1 trial
fulvestrant RxCUI 282357 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting
1 trial
metformin RxCUI 6809 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting
1 trial
niraparib RxCUI 1918231 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting
1 trial
tamoxifen RxCUI 10324 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting
1 trial
toremifene RxCUI 38409 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting
1 trial
Sponsor roles
lead sponsor29
collaborator22
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.